Trial Profile

Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-19 vaccine (Primary) ; Elasomeran (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Therapeutic Use
Acronyms CoVPN3008; UBUNTU

Most Recent Events

13 May 2024 Status changed from active, no longer recruiting to completed.
06 Mar 2024 Results assessing the safety of mRNA-1273, the effectiveness of hybrid versus vaccine immunity, and SARS-CoV-2 viral persistence among people with HIV, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
13 Nov 2023 Planned End Date changed from 24 Apr 2024 to 12 Apr 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com